Anaplastic large cell lymphoma: one or more entities among T-cell lymphoma?

被引:41
|
作者
Fornari, Alessandro [1 ,2 ]
Piva, Roberto [1 ,2 ,3 ]
Chiarle, Roberto [1 ,2 ]
Novero, Domenico [1 ,2 ]
Inghirami, Giorgio [1 ,2 ,3 ]
机构
[1] Univ Turin, Dept Pathol, I-10126 Turin, Italy
[2] Univ Turin, Ctr Expt Res & Med Studies, I-10126 Turin, Italy
[3] NYU, Sch Med, Ctr Canc, Dept Pathol, New York, NY USA
关键词
ALCL; ALK; T-cell lymphoma; RECEPTOR TYROSINE KINASE; NON-HODGKINS-LYMPHOMA; POLYMERASE-CHAIN-REACTION; ALK-POSITIVE LYMPHOMA; NPM-ALK; GROWTH-FACTOR; GENE-EXPRESSION; KI-1; LYMPHOMA; T(2-5)(P23-Q35) TRANSLOCATION; FUSION PROTEIN;
D O I
10.1002/hon.897
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Anaplastic large cell lymphoma (ALCL) is a subtype of peripheral T-cell lymphoma (PTCL) first described in 1985 as a lymphoid malignancy characterized by marked cellular pleomorphism propensity to grow cohesively, tendency to invade lymph node sinuses and diffuse expression of CD30 [1]. The discovery or the t(2;5), involving the anaplastic lymphoma kinase (ALK) gene on chromosome 2 and the nucleophosmin (NPM) gene on chromosome 5 in the majority of systemic ALCL, has soon pointed out that ALCL is a clinically and biologically heterogeneous disease. While ALK-positive (ALK+) ALCL is usually characterized by onset in children and young adults and better prognosis, epidemiology, poor outcome and possibly genetic detects of ALK-negative (ALK-) ALCL suggest that this neoplasms should be considered an independent pathological entity. The aim or this review is to illustrate clinical features, histology, immunophenotype, genetics and biology of ALCL and discuss possible relationship(s) among different T-non-Hodgkin lymphoma (T-NHL). Copyright (C) 2009 John Wiley & Sons, Ltd.
引用
收藏
页码:161 / 170
页数:10
相关论文
共 50 条
  • [21] Analysis of Human T-Cell Lymphotropic Virus in CD25+ Anaplastic Large Cell Lymphoma in Children
    Gualco, Gabriela
    Chioato, Lucimara
    Weiss, Lawrence M.
    Harrington, William J., Jr.
    Bacchi, Carlos E.
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2009, 132 (01) : 28 - 33
  • [22] Primary cutaneous CD30(+) ALK(-) anaplastic large cell T-cell lymphoma
    Muehloff, C.
    Ruebben, A.
    Gassler, N.
    Megahed, M.
    HAUTARZT, 2009, 60 (12): : 954 - 956
  • [23] The ALK inhibitor ASP3026 eradicates NPM-ALK+ T-cell anaplastic large-cell lymphoma in vitro and in a systemic xenograft lymphoma model
    George, Suraj Konnath
    Vishwamitra, Deeksha
    Manshouri, Roxsan
    Shi, Ping
    Amin, Hesham M.
    ONCOTARGET, 2014, 5 (14) : 5750 - 5763
  • [24] Anaplastic Lymphoma Kinase as a Therapeutic Target in Anaplastic Large Cell Lymphoma, Non-Small Cell Lung Cancer and Neuroblastoma
    Cheng, Mangeng
    Ott, Gregory R.
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2010, 10 (03) : 236 - 249
  • [25] The many faces of anaplastic large cell lymphoma
    Foss, HD
    Marafioti, T
    Stein, H
    PATHOLOGE, 2000, 21 (02): : 124 - 136
  • [26] Anaplastic large cell lymphoma: A clinicopathologic analysis
    Skinnider, BF
    Connors, JM
    Sutcliffe, SB
    Gascoyne, RD
    HEMATOLOGICAL ONCOLOGY, 1999, 17 (04) : 137 - 148
  • [27] Anaplastic Large Cell Lymphoma in Children and Adolescents
    Lowe, Eric J.
    Gross, Thomas G.
    PEDIATRIC HEMATOLOGY AND ONCOLOGY, 2013, 30 (06) : 509 - 519
  • [28] Uniform expression of cytotoxic molecules in anaplastic large cell lymphoma of null T cell phenotype and in cell lines derived from anaplastic large cell lymphoma
    Foss, HD
    Demel, G
    Anagnostopoulos, I
    Araujo, I
    Hummel, M
    Stein, H
    PATHOBIOLOGY, 1997, 65 (02) : 83 - 90
  • [29] Primary anaplastic large cell lymphoma of the kidney
    Venizelos, ID
    Rombis, V
    Tulupidis, S
    Caripidou, V
    LEUKEMIA & LYMPHOMA, 2003, 44 (02) : 353 - 355
  • [30] Primary gastrointestinal anaplastic large cell lymphoma
    Lee, Yi-Ying
    Takata, Katsuyoshi
    Wang, Ren-Ching
    Yang, Sheau-Fang
    Chuang, Shih-Sung
    PATHOLOGY, 2017, 49 (05) : 479 - 485